文献速递胸部肿瘤

对侧食管保护技术在局部晚期肺癌高剂量放化疗中的评估:1期非随机临床试验

Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation: A Phase 1 Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2021-01-01

这项单中心1期非随机试验评估了对侧食管保护技术,入组27例肿瘤距食管1 cm内的局部晚期肺癌患者,接受70 Gy调强放疗联合同步化疗。可评估的20例患者中3级及以上急性食管炎发生率为0%,2年无进展生存率57%,总生存率67%。

要点

  • 对侧食管保护技术联合70 Gy放化疗,可评估患者3级及以上急性食管炎发生率为0%。
  • 2年无进展生存率57%(95%CI 33%-75%),2年总生存率67%(95%CI 45%-82%)。
  • 全部25例完成放化疗患者中,7例(28%)发生2级食管炎,3例(12%)发生2级及以上肺炎(含1例5级)。

核心结论

  • 对侧食管保护技术在接受70 Gy同步放化疗的局部晚期肺癌患者中与严重急性食管炎风险降低相关。
  • 尽管肿瘤距食管1 cm以内,未观察到3级及以上急性食管炎。
  • 该技术可能转化至临床实践。

研究设计与样本

  • 单中心1期非随机临床试验,2015年7月至2019年1月入组27例局部晚期非小细胞肺癌(可伴孤立脑转移)或局限期小细胞肺癌患者。
  • 肿瘤距食管1 cm以内,接受70 Gy/2 Gy分次调强放疗联合同步标准化疗,可加用辅助度伐利尤单抗。
  • 将对侧食管壁勾画为避让结构以引导陡峭剂量跌落,靶区覆盖优先于对侧食管保护。

主要发现

  • 27例入组患者中25例完成放化疗,19例为非小细胞肺癌,6例为小细胞肺癌。
  • 中位年龄67岁(范围51-81岁),15例(60%)为男性。
  • 对侧食管中位最大剂量66 Gy(范围44-71 Gy),中位V55 Gy为1.4 cm3(范围0-5.3 cm3),中位V45 Gy为2.7 cm3(范围0-9.2 cm3)。
  • 中位随访33.3个月(范围11.1-52.2个月),20例可评估患者中3级及以上食管炎发生率为0%。

关键数值与推荐

  • 主要终点为 Common Terminology Criteria for Adverse Events 第4版评估的3级及以上急性食管炎发生率。
  • 99%的内靶区必须被70 Gy覆盖,至少63 Gy覆盖99%的计划靶区。
  • 全部25例患者中,7例(28%)发生2级食管炎,3例(12%)发生2级及以上肺炎(含1例5级),2例(8%)发生3级及以上心脏毒性事件(含1例5级)。
  • 无孤立局部肿瘤失败,2年无进展生存率57%(95%CI 33%-75%),2年总生存率67%(95%CI 45%-82%)。

临床怎么用

  • 对肿瘤紧邻食管的局部晚期肺癌患者,可将对侧食管壁作为避让结构以降低严重急性食管炎风险。
  • 实施时需确保靶区覆盖优先,99%内靶区接受70 Gy、99%计划靶区至少接受63 Gy。
  • 该技术联合70 Gy放化疗在可评估患者中未观察到3级及以上急性食管炎。

局限性

  • 单中心1期非随机试验,样本量小(27例入组,25例完成治疗,20例可评估主要终点)。
  • 缺乏对照组,无法直接比较对侧食管保护技术与标准放疗的差异。
  • 主要终点仅纳入治疗中断0-3天的可评估患者,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Severe acute esophagitis occurs in up to 20% of patients with locally advanced lung cancer treated with chemoradiation therapy to at least 60 Gy once daily and represents a dose-limiting toxic event associated with poor outcomes. OBJECTIVE: To assess whether formalized sparing of the contralateral esophagus (CE) is associated with reduced risk of severe acute esophagitis. DESIGN, SETTING, AND PARTICIPANTS: This single-center phase 1 nonrandomized clinical trial assessing an empirical CE-sparing technique enrolled patients from July 2015 to January 2019. In total, 27 patients with locally advanced non-small cell lung carcinoma (with or without solitary brain metastasis) or limited-stage small cell lung carcinoma with gross tumor within 1 cm of the esophagus were eligible. INTERVENTIONS: Intensity-modulated radiation therapy to 70 Gy at 2 Gy/fraction concurrent with standard chemotherapy with or without adjuvant durvalumab. The esophageal wall contralateral to gross tumor was contoured as an avoidance structure to guide a steep dose falloff gradient. Target coverage was prioritized over CE sparing, and 99% of internal and planning target volumes had to be covered by 70 Gy and at least 63 Gy, respectively. MAIN OUTCOMES AND MEASURES: The primary end point was the rate of at least grade 3 acute esophagitis as assessed by Common Terminology Criteria for Adverse Events, version 4. RESULTS: Of 27 patients enrolled, 25 completed chemoradiation therapy. Nineteen patients had non-small cell lung carcinoma, and 6 had small cell lung carcinoma. The median age at diagnosis was 67 years (range, 51-81 years), and 15 patients (60%) were men. Thirteen patients (52%) had stage IIIA cancer, 10 (40%) had stage IIIB cancer, and 2 (8%) had stage IV cancer. The median CE maximum dose was 66 Gy (range, 44-71 Gy); the median volume of CE receiving at least 55 Gy was 1.4 cm3 (range, 0-5.3 cm3), and the median volume of CE receiving at least 45 Gy was 2.7 cm3 (range, 0-9.2 cm3). The median combined percentage of lung receiving at least 20 Gy was 25% (range, 11%-37%). The median follow-up was 33.3 months (range, 11.1-52.2 months). Among the 20 patients who had treatment breaks of 0 to 3 days and were thus evaluable for the primary end point, the rate of at least grade 3 esophagitis was 0%. Other toxic events observed among all 25 patients included 7 (28%) with grade 2 esophagitis, 3 (12%) with at least grade 2 pneumonitis (including 1 with grade 5), and 2 (8%) with at least grade 3 cardiac toxic event (including 1 with grade 5). There was no isolated local tumor failure. The 2-year progression-free survival rate was 57% (95% CI, 33%-75%), and the 2-year overall survival rate was 67% (95% CI, 45%-82%). CONCLUSIONS AND RELEVANCE: This phase 1 nonrandomized clinical trial found that the CE-sparing technique was associated with reduced risk of esophagitis among patients treated uniformly with chemoradiation therapy (to 70 Gy), with no grade 3 or higher esophagitis despite tumor within 1 cm of the esophagus. This technique may be translated into clinical practice. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02394548.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Kamran SC, Yeap BY, Ulysse CA, et al. Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncol. 2021. PMID: 33830168. doi:10.1001/jamaoncol.2021.0281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。